It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...
Neuphoria Therapeutics’ lead candidate has failed to improve social anxiety symptoms in a late-stage trial, prompting the ...
Unless a white knight emerges to rescue the business, Galapagos will start a wind-down process that will affect around 365 ...
A retinal implant developed by Science Corp. has for the first time restored some functional vision to patients with a severe ...
Under the terms of a deal that rescued the once-rejected tebipenem HBr, GSK will file for approval of the oral antibiotic. Back in 2022, after the FDA requested another phase 3 trial and denied ...
Meanwhile, AstraZeneca’s Enhertu partner Daiichi arrived at ESMO armed with its own ADC data for the cadherin-6-targetting ...
After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval ...
BioNTech won’t proceed with further development of its BNT111 cancer vaccine candidate in a specific late-stage refractory ...
The U.S. private equity market is showing signs of recovery, with strong deal activity and lower interest rates driving ...
Boston Scientific shelled out $533 million to buy up the remaining equity it had in Nalu Medical, a private company that ...
Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to ...
Roche believes it has exited phase 3 with data to support talks with regulatory agencies, but the mixed results raise ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback